CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
N-acetylcysteine +1 moredrug
Likely dose
N-acetylcysteine 900 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00568087
NCT00568087Phase 2Completed
CompareCT.gov

N-acetylcysteine in Alcohol Dependence

Minneapolis Veterans Affairs Medical Center·interventional·Posted Dec 5, 2007·Updated Mar 18, 2020

In Brief

A Phase 2 clinical trial evaluating N-acetylcysteine and Placebo for Alcoholism. Completed, enrolled 46 participants across 1 site.

Detailed Summary

The present study is designed to find out if N-acetylcysteine works in reducing alcohol drinking and craving.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsMinnesota Veterans Medical Research and Education Foundation

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2007
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.6 years ago

Interventions

N-acetylcysteinedrug

Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.

Placebodrug

Patients will take oral placebo (identical matching placebo) during the study period.